New antibody therapy shows promise Pediatric brain

Written By :  Isra Zaman
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-07-19 04:00 GMT   |   Update On 2022-07-19 04:00 GMT

Effective and safe treatments are needed for medulloblastoma, the most common type of cancerous brain tumor in children, especially whose cancer has spread to the spinal cord. A recent phase I clinical trial led by researchers has generated promising results for a new blocking antibody therapy that targets a protein critical to medulloblastoma cells' ability to multiply and spread....

Login or Register to read the full article

Effective and safe treatments are needed for medulloblastoma, the most common type of cancerous brain tumor in children, especially whose cancer has spread to the spinal cord. A recent phase I clinical trial led by researchers has generated promising results for a new blocking antibody therapy that targets a protein critical to medulloblastoma cells' ability to multiply and spread. The findings are published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

The antibody, called TB-403, recognizes placental growth factor (PlGF), over-expressed in some types of malignant tumors. The MGH research team previously showed that placental growth factor and its receptor neuropilin 1 (NRP1) are often overexpressed in human medulloblastomas and are required for its growth and progression in experimental models in mice.

That work also demonstrated that blocking the PlGF/NRP1 pathway in medulloblastoma models caused tumor regression, decreased spread to the spinal cord, and prolonged survival.

The investigators' phase I, open-label, multicenter dose-escalation study enrolled 15 children with relapsed or refractory medulloblastoma that did not respond to standard treatments. Patients received increasing doses of the anti-human placental growth factor antibody TB-403 (20 mg/kg, 50 mg/kg, 100 mg/kg, and 175 mg/kg), and all patients received two doses of TB-403 in the first cycle of treatment.

The maximum tolerated dose defined in clinical trials as the highest dose of a drug that does not cause unacceptable toxicity-was not reached. Moreover, although there were no partial tumor responses (significant reductions in tumor size) in this treatment refractory population, seven of 11 patients experienced disease stabilization-stoppage of progression-and which persisted for more than 100 days in four of those patients.

The investigators concluded that TB403 treatment was well tolerated and induced stable disease in some medulloblastomas in a setting with no effective treatments available.

These findings indicate that treatment with TB-403 should be tested in larger studies of children with advanced medulloblastoma and perhaps at earlier stages, in combination with standard therapies, concluded the researchers.

Reference: "New antibody therapy shows promising phase I clinical trial results for advanced, treatment-refractory pediatric brain cancer; MASSACHUSETTS GENERAL HOSPITAL,Clinical Cancer Research.

Tags:    
Article Source : American Association for Cancer Research.

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News